SOS1::KRAS inhibitor (BI 1701963): mechanism of action

Our Son of sevenless homolog 1::Kirsten rat sarcoma (SOS1::KRAS) inhibitor is a small molecule that binds to SOS1, reducing the formation of active, guanosine triphosphate (GTP)-loaded KRAS. The KRAS guanosine diphosphate (GDP)–GTP cycle is regulated by guanine nucleotide exchange factors (such as SOS1) that promote nucleotide exchange and formation of ‘active’ KRAS–GTP. This SOS1::KRAS inhibitor is currently undergoing clinical investigation in patients with KRAS mutation-positive solid tumours.
BI 1701963 is an investigational compound and has not been approved. Its safety and efficacy has not been established.

For more information visit: https://www.boehringer-ingelheim.com/...

Click on the red button above to subscribe to our YouTube channel.

Taking cancer on by directly targeting cancer cells is a fundamental treatment strategy. We are working to further unlock the power of cancer cell-directed therapies. Our focus, passion and commitment, combined with our strong collaborations, will help us transform expectations, give hope to more patients and help win the fight against cancer.

For more information about the currently enrolling Phase I study of this compound, visit: https://www.mystudywindow.com/trial/l....